0000899243-21-006715.txt : 20210216 0000899243-21-006715.hdr.sgml : 20210216 20210216174852 ACCESSION NUMBER: 0000899243-21-006715 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210211 FILED AS OF DATE: 20210216 DATE AS OF CHANGE: 20210216 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: DAVIS JOHN C. JR CENTRAL INDEX KEY: 0001741287 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38541 FILM NUMBER: 21641392 MAIL ADDRESS: STREET 1: C/O MAGENTA THERAPEUTICS STREET 2: 50 HAMPSHIRE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Magenta Therapeutics, Inc. CENTRAL INDEX KEY: 0001690585 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 100 TECHNOLOGY SQUARE STREET 2: 5TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 857-201-2700 MAIL ADDRESS: STREET 1: 100 TECHNOLOGY SQUARE STREET 2: 5TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-02-11 0 0001690585 Magenta Therapeutics, Inc. MGTA 0001741287 DAVIS JOHN C. JR C/O MAGENTA THERAPEUTICS, INC. 100 TECHNOLOGY SQUARE CAMBRIDGE MA 02139 0 1 0 0 See Remarks Stock Option (Right to Buy) 10.80 2021-02-11 4 A 0 72500 0.00 A 2031-02-10 Common Stock 72500 72500 D This option shall vest and become exercisable in 16 equal quarterly installments beginning on January 1, 2021. Title: Head of Research and Development and Chief Medical Officer /s/ Zoran Zdraveski, Attorney-in-Fact for John C. Davis Jr. 2021-02-16